KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Research & Development (2017 - 2025)

Twist Bioscience (TWST) has disclosed Research & Development for 9 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 19.6% to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.1 million through Dec 2025, down 14.54% year-over-year, with the annual reading at $80.3 million for FY2025, 11.63% down from the prior year.
  • Research & Development for Q4 2025 was $17.1 million at Twist Bioscience, up from $17.0 million in the prior quarter.
  • The five-year high for Research & Development was $36.8 million in Q2 2022, with the low at $15.8 million in Q1 2021.
  • Average Research & Development over 5 years is $23.5 million, with a median of $22.9 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 97.78% in 2022, then plummeted 33.42% in 2023.
  • Over 5 years, Research & Development stood at $22.6 million in 2021, then skyrocketed by 38.06% to $31.2 million in 2022, then fell by 26.06% to $23.1 million in 2023, then fell by 7.76% to $21.3 million in 2024, then decreased by 19.6% to $17.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $17.1 million, $17.0 million, and $18.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.